{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:29:55Z","timestamp":1788348595694,"version":"build-2803163510"},"reference-count":35,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The majority of patients with chronic graft-versus-host disease (cGVHD) are steroid refractory (SR), creating a need for safe and effective therapies. Subcutaneous low-dose interleukin-2 (LD IL-2), which preferentially expands CD4+ regulatory T cells (Tregs), has been evaluated in 5 clinical trials at our center with partial responses (PR) in \u223c50% of adults and 82% of children by week 8. We now report additional real-world experience with LD IL-2 in 15 children and young adults. We conducted a retrospective chart review of patients with SR-cGVHD at our center who received LD IL-2 from August 2016 to July 2022 not on a research trial. The median age at start of LD IL-2 was 10.4 years (range, 1.2-23.2 years) at a median of 234\u00a0days from cGVHD diagnosis (range, 11-542\u00a0days). Patients had a median of 2.5 (range, 1-3) active organs at LD IL-2 start and received a median of 3 (range, 1-5) prior therapies. The median duration of LD IL-2 therapy was 462\u00a0days (range, 8-1489\u00a0days). Most patients received 1\u00a0\u00d7 106 IU\/m2 per day. There were no serious adverse effects. The overall response rate in 13 patients who received &amp;gt;4\u00a0weeks of therapy was 85% (complete response, n\u00a0= 5; PR, n\u00a0= 6) with responses in diverse organs. Most patients significantly weaned corticosteroids. Tregs preferentially expanded with a median peak fold increase of 2.8 in the ratio of Tregs to CD4+ conventional T cells (range, 2.0-19.8) by 8\u00a0weeks on therapy. LD IL-2 is a well-tolerated, steroid-sparing agent with a high response rate in children and young adults with SR-cGVHD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009729","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T21:03:46Z","timestamp":1684962226000},"page":"4647-4657","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-3184","authenticated-orcid":false,"given":"Holly","family":"Wobma","sequence":"first","affiliation":[{"name":"1Division of Immunology, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Kapadia","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"4Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-8431","authenticated-orcid":false,"given":"Francesca","family":"Alvarez-Calderon","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne H. C.","family":"Baumeister","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Duncan","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-7947","authenticated-orcid":false,"given":"Suzanne","family":"Forrest","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-2276","authenticated-orcid":false,"given":"Lev","family":"Gorfinkel","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Huang","sequence":"additional","affiliation":[{"name":"1Division of Immunology, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie E.","family":"Lehmann","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojun","family":"Li","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-0150","authenticated-orcid":false,"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie S.","family":"Kean","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-2532","authenticated-orcid":false,"given":"Jennifer S.","family":"Whangbo","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"issue":"1","key":"2023082115343933600_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","article-title":"Chronic graft-versus-host disease (GVHD) in children","volume":"57","author":"Baird","year":"2010","journal-title":"Pediatr Clin North Am"},{"issue":"17","key":"2023082115343933600_bib2","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2023082115343933600_bib3","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023082115343933600_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2023082115343933600_bib5","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2011-06-362137","article-title":"Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation","volume":"118","author":"Kawano","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2023082115343933600_bib6","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2023082115343933600_bib7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","article-title":"Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2023082115343933600_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.2019000953","article-title":"Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease","volume":"136","author":"Toubai","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023082115343933600_bib9","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: treatment options and patient management","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2023082115343933600_bib10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood.2021014448","article-title":"Three US Food and Drug Administration\u2013approved therapies for chronic GVHD","volume":"139","author":"Zeiser","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023082115343933600_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2016-08-686659","article-title":"Mechanistic approaches for the prevention and treatment of chronic GVHD","volume":"129","author":"Cutler","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023082115343933600_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.immuni.2008.11.014","article-title":"A\u00a0low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells","volume":"30","author":"Yu","year":"2009","journal-title":"Immunity"},{"issue":"179","key":"2023082115343933600_bib13","doi-asserted-by":"crossref","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"issue":"7","key":"2023082115343933600_bib14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/bloodadvances.2018027474","article-title":"Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv"},{"issue":"18","key":"2023082115343933600_bib15","doi-asserted-by":"crossref","first-page":"e89278","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"2023082115343933600_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023082115343933600_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/bloodadvances.2018029124","article-title":"Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease","volume":"3","author":"Belizaire","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"2023082115343933600_bib18","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2023082115343933600_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2023082115343933600_bib20","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2023082115343933600_bib21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-vs-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N\u00a0Eng J Med"},{"issue":"9","key":"2023082115343933600_bib22","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","article-title":"Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I\/II randomised, double-blind, placebo-controlled, dose-finding study","volume":"63","author":"Rosenzwajg","year":"2020","journal-title":"Diabetologia"},{"issue":"2","key":"2023082115343933600_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2023082115343933600_bib24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2023082115343933600_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023082115343933600_bib26","doi-asserted-by":"publisher","DOI":"10.1101\/2022.11.15.22282201","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and gatekeeper features","author":"Raeber","year":"2022","journal-title":"medRxiv"},{"issue":"6","key":"2023082115343933600_bib27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in\u00a0vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2023082115343933600_bib28","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001379","article-title":"Impact of immune-modulatory drugs on regulatory T cell","volume":"100","author":"Furukawa","year":"2016","journal-title":"Transplantation"},{"issue":"15","key":"2023082115343933600_bib29","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1182\/bloodadvances.2022007773","article-title":"Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host-disease","volume":"6","author":"Kim","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2023082115343933600_bib30","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/bloodadvances.2019001248","article-title":"IL-2 enhances ex\u00a0vivo-expanded regulatory T-cell persistence after adoptive transfer","volume":"4","author":"Furlan","year":"2020","journal-title":"Blood Adv"},{"issue":"6379","key":"2023082115343933600_bib31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"8","key":"2023082115343933600_bib32","doi-asserted-by":"crossref","first-page":"e139991","DOI":"10.1172\/JCI139991","article-title":"Selective expansion of regulatory T cells using an orthogonal IL-2\/IL-2 receptor system facilitates transplantation tolerance","volume":"131","author":"Hirai","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2023082115343933600_bib33","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/s41467-022-31130-9","article-title":"Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein","volume":"13","author":"de Picciotto","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"2023082115343933600_bib34","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.4049\/jimmunol.1800907","article-title":"IL-2\/CD25: a long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 Receptor on regulatory T cells","volume":"201","author":"Ward","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"24","key":"2023082115343933600_bib35","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4647\/2072591\/blooda_adv-2023-009729-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4647\/2072591\/blooda_adv-2023-009729-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:35:09Z","timestamp":1692632109000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4647\/496006\/Real-world-experience-with-low-dose-IL-2-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":35,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009729","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]}}}